Wendy F. Dicicco net worth and biography

Wendy Dicicco Biography and Net Worth

Ms. DiCicco serves as an independent financial and board advisor to companies in the life sciences industry, often serving in the role of interim Chief Financial Officer. Since July 2023 she has served as the interim Chief Financial Officer for Akari Therapeutics (NASDAQ: AKTX). From 2019 to March 2022, she served as interim Chief Financial Officer for Renovacor, a preclinical stage biopharmaceutical company (NYSE: RCOR). Previously, she was Chief Operating and Financial Officer of Centinel Spine from 2017 to 2018, a privately held company. Ms. DiCicco currently serves on the board of directors of Imvax, Inc a privately held biotechnology company, and previously served on the boards of directors of SWK Holdings Corp (NASDAQ:SWKH), Sincerus Pharmaceuticals, ExpressCells, II-VI, Inc. (NASDAQ: II-VI), Carmell Therapeutics, Syncardia Systems and CannaPharma Rx (OTC: CPMD). She previously served as President and Chief Operating Officer of Camber Spine Technologies and has held Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche in 1990. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD).

What is Wendy F. Dicicco's net worth?: The estimated net worth of Wendy F. Dicicco is at least $166.65 thousand as of August 20th, 2024. Dicicco owns 9,967 shares of Eyepoint Pharmaceuticals stock worth more than $166,648 as of December 5th. This net worth approximation does not reflect any other assets that Dicicco may own. Learn More about Wendy F. Dicicco's net worth.
How do I contact Wendy F. Dicicco?: The corporate mailing address for Dicicco and other Eyepoint Pharmaceuticals executives is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. Eyepoint Pharmaceuticals can also be reached via phone at (617) 926-5000 and via email at [email protected]. Learn More on Wendy F. Dicicco's contact information.
Has Wendy F. Dicicco been buying or selling shares of Eyepoint Pharmaceuticals?: Wendy F. Dicicco has not been actively trading shares of Eyepoint Pharmaceuticals within the last three months. Most recently, on Tuesday, August 20th, Wendy F. Dicicco bought 2,567 shares of Eyepoint Pharmaceuticals stock. The stock was acquired at an average cost of $7.79 per share, with a total value of $19,996.93. Following the completion of the transaction, the director now directly owns 9,967 shares of the company's stock, valued at $77,642.93. Learn More on Wendy F. Dicicco's trading history.
Who are Eyepoint Pharmaceuticals' active insiders?: Eyepoint Pharmaceuticals' insider roster includes Wendy Dicicco (Director), and David Jones (Chief Commercial Officer). Learn More on Eyepoint Pharmaceuticals' active insiders.

Wendy F. Dicicco Insider Trading History at Eyepoint Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/20/2024	Buy	2,567	$7.79	$19,996.93	9,967

Wendy F. Dicicco Buying and Selling Activity at Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals Company Overview

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $16.72

$14.40

$17.00

50 Day Range

MA: $13.00

$11.02

$16.72

2 Week Range

Now: $16.72

$3.91

$17.00

Volume

2,029,677 shs

Average Volume

1,004,794 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield